CDHA CAAR

“Medicare Part B Drug Payments: Impact of Price Substitutions Based on 2017 Average Sales Prices,” (OEI-03-19-00260, August 2019, .pdf format, 12p.).

oig.hhs.gov/oei/reports/oei-03-19-00260.asp

“A Look at Recent Proposals to Control Drug Spending by Medicare and its Beneficiaries,” by Meredith Freed, Juliette Cubanski, and Tricia Neuman (August 2019, HTML and .pdf format, 27p.).

www.kff.org/medicare/issue-brief/a-look-at-recent-proposals-to-control-drug-spending-by-medicare-and-its-beneficiaries/

“How Many Medicare Part D Enrollees Had High Out-of-Pocket Drug Costs in 2017?” by Juliette Cubanski, Tricia Neuman, and Anthony Damico (June 2019, .pdf format, 12p.).

www.kff.org/medicare/issue-brief/how-many-medicare-part-d-enrollees-had-high-out-of-pocket-drug-costs-in-2017/

“The Effect of Medicare Part D on Evergreening, Generic Entry, and Drug Prices,” by Geoffrey T. Sanzenbacher and Gal Wettstein (WP No.2019-8, May 2019, .pdf and Excel format, 24p.). Note: Links to the abstract and the full text of this paper available at:

crr.bc.edu/working-papers/the-effect-of-medicare-part-d-on-evergreening-generic-entry-and-drug-prices/

“The Out-of-Pocket Cost Burden for Specialty Drugs in Medicare Part D in 2019,” by Juliette Cubanski, Wyatt Koma, and Tricia Neuman (January 2019, .pdf and HTML format, 16p.).

www.kff.org/medicare/issue-brief/the-out-of-pocket-cost-burden-for-specialty-drugs-in-medicare-part-d-in-2019/

“Proposed Changes to Medicare Part D Would Benefit Drug Manufacturers More Than Beneficiaries,” by Shawn Bishop (January 2019).

www.commonwealthfund.org/blog/2019/proposed-changes-medicare-part-d-would-benefit-drug-manufacturers-more-beneficiaries

“Medicare Part B Drug Payments: Impact of Price Substitutions Based on 2016 Average Sales Prices,” (OEI-03-18-00120, August 2018, .pdf format, 12p.).

oig.hhs.gov/oei/reports/oei-03-18-00120.asp

“Increases in Reimbursement for Brand-Name Drugs in Part D,” (OEI 03 15 00080, June 2018, .pdf format, 15p.).

oig.hhs.gov/oei/reports/oei-03-15-00080.asp

“No Limit: Medicare Part D Enrollees Exposed to High Out-of-Pocket Drug Costs Without a Hard Cap on Spending,” by Juliette Cubanski, Tricia Neuman, Kendal Orgera, and Anthony Damico (November 2017, .pdf and HTML format, 13p.).

www.kff.org/medicare/issue-brief/no-limit-medicare-part-d-enrollees-exposed-to-high-out-of-pocket-drug-costs-without-a-hard-cap-on-spending/

A. “Medicare Part D: A First Look at Prescription Drug Plans in 2018,” by Juliette Cubanski, Anthony Damico, Jack Hoadley, Kendal Orgera, and Tricia Neuman (October 2017, .pdf and HTML format, 21p.).

www.kff.org/medicare/issue-brief/medicare-part-d-a-first-look-at-prescription-drug-plans-in-2018/

B. “Medicare Advantage 2018 Data Spotlight: First Look,” by Gretchen Jacobson, Anthony Damico, and Tricia Neuman (October 2017, .pdf and HTML format, 5p.).

www.kff.org/medicare/issue-brief/medicare-advantage-2018-data-spotlight-first-look/

“Generic Drugs Under Medicare: Part D Generic Drug Prices Declined Overall, but Some Had Extraordinary Price Increases,” (GAO-16-706, August 2016, .pdf format, 52p.).

www.gao.gov/products/GAO-16-706

“CMS Should Address Medicare’s Flawed Payment System for DME Infusion Drugs,” (OEI-12-16-00340, September 2016, .pdf format, 11p.).

oig.hhs.gov/oei/reports/oei-12-16-00340.asp